Streetbeat News

Regulatory

KA

Kineta has reopened enrollment for its Oncoinc VISTA-101 clinical trial, which is evaluating the drug KVA12123 in patients with advanced solid tumor cancer. This development is significant for the company's progress in cancer treatment research.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:03 pm

FFIEW

Trading for FFIEW was halted and has now resumed as of 9:00 AM ET. The halt was due to pending news, which has now been released, allowing trading to continue.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:00 pm

SONN

Sonnet BioTherapeutics has entered a clinical collaboration with the Sarcoma Oncology Center to conduct a Phase 1/2a study of SON-1210, a bifunctional IL-12/IL-15 fusion protein, in combination with chemotherapy for pancreatic cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:46 pm

ALZN

LQDA

ZIM

Alzamend Neuro partners with Massachusetts General Hospital for a Phase II study of AL001 for PTSD, boosting shares by 248%. ZIM Integrated Shipping Services reports strong Q2 results and raises FY24 guidance, increasing shares by 18%. Liquidia's shares drop 40% after FDA grants tentative approval for YUTREPIA.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:36 pm

CDXC

ChromaDex has been granted a U.S. patent for the composition of matter for the disodium salt of NMNH, which could enhance its intellectual property portfolio and potentially impact its market position.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:33 pm

TLPH

Talphera has announced the enrollment of the first patient in its registrational trial for Nafamostat, aimed at anticoagulation in the extracorporeal circuit. This marks a significant step in the development of their product pipeline.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:33 pm

COP

MRO

Marathon Oil has received demand letters and complaints from stockholders concerning its deal with ConocoPhillips. In response, Marathon Oil has voluntarily issued additional disclosures while denying all allegations.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:33 pm

LQDA

MREO

SERV

SHAK

YXT

Several stocks experienced declines in Monday's pre-market session. Liquidia Corporation saw a significant drop after FDA's tentative approval of YUTREPIA. Shake Shack was downgraded by Piper Sandler, contributing to its decline. Other stocks like YXT.COM, Mereo BioPharma, and Serve Robotics also faced losses.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 12:27 pm

EBS

GOVX

VRAX

Shares of vaccine and mpox-related stocks are trading higher following the WHO's declaration of the virus as a global health emergency last week.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:16 pm

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:04 pm